Clinical Trial Update: IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating IBI310 in combination with sintilimab for advanced biliary tract cancer is ongoing; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• IBI310 (IBI310)
• Sintilimab (sintilimab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Advanced Biliary Tract Cancer | Phase 1, Phase 2 | Status: UNKNOWN